# Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

> **NCT01880385** · PHASE1 · UNKNOWN · sponsor: **Association Tunisienne de lutte Contre le Cancer** · enrollment: 30 (estimated)

## Conditions studied

- Inflammatory Breast Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Cyclophosphamide
- **DRUG:** epirubicin hydrochloride
- **DRUG:** fluorouracil
- **DRUG:** Docetaxel
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT01880385
- **Lead sponsor:** Association Tunisienne de lutte Contre le Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2013-09
- **Final completion:** 2017-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01880385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01880385, "Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01880385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*